Revolution Medicines (RVMD) Accumulated Expenses (2019 - 2026)

Revolution Medicines' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $192.5 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 96.15% year-over-year to $192.5 million in Q1 2026; TTM through Mar 2026 was $192.5 million, a 96.15% increase from a year earlier, with the FY2025 full-year figure at $58.2 million, down 39.77% from the prior year.
• Accumulated Expenses improved to $192.5 million in Q1 2026 per RVMD's latest filing, from $58.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $192.5 million in Q1 2026 and bottomed at $4.2 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $53.2 million (2024), against an average of $63.1 million.
• Across the five-year window, Accumulated Expenses slumped 79.21% in 2022 and surged 810.37% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $29.4 million in 2022, then surged by 153.66% to $74.7 million in 2023, then grew by 29.35% to $96.6 million in 2024, then plunged by 39.77% to $58.2 million in 2025, then soared by 230.72% to $192.5 million in 2026.
• Per Business Quant, the three latest RVMD Accumulated Expenses figures stand at $192.5 million (Q1 2026), $58.2 million (Q4 2025), and $154.4 million (Q3 2025).